There are currently 161 active clinical trials seeking participants for Lung Cancer research studies. The states with the highest number of trials for Lung Cancer participants are Ohio, California, Illinois and Michigan.
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228
Recruiting
This is a multicenter, open-label, Phase 1 study of orally administered VMD-928 in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/18/2025
Locations: Providence Medical Foundation (site 209), Santa Rosa, California +14 locations
Conditions: Mesothelioma, Ovarian Cancer, Adenoid Cystic Carcinoma, Cervical Cancer, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymic Carcinoma, Bladder Cancer, Pancreatic Cancer, Head and Neck Carcinoma, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Sarcoma, Esophageal Cancer, Uterine Cancer, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma
Register for Updates
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
NCT06698042
Recruiting
Researchers are looking for new ways to treat non-small cell lung cancer (NSCLC) that is metastatic, which means cancer has spread to other parts of the body. Some people with metastatic NSCLC are treated with pembrolizumab, an immunotherapy treatment that is given into a vein as an intravenous (IV) infusion. Pembrolizumab (+) Berahyaluronidase alfa is pembrolizumab that is given under the skin as a subcutaneous (SC) injection. The goal of this study is to compare what happens to pembrolizumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Providence Medical Foundation ( Site 0117), Fullerton, California +60 locations
Conditions: Lung Cancer, Non-Small Cell Lung Cancer
Register for Updates
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
NCT06410300
Recruiting
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of Missouri - Ellis Fischel Cancer Center, Columbia, Missouri +2 locations
Conditions: Lung Cancer
Register for Updates
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
NCT04105270
Recruiting
This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Adenocarcinoma of Lung, Lung Cancer
Register for Updates
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
NCT06910956
Recruiting
The goal of this clinical trial is to evaluate whether an AI tool that alerts providers to patients at high 6-year risk of lung cancer based on their chest x-ray images will improve lung cancer screening CT participation. The main question it aims to answer is: Does the AI tool improve lung cancer screening CT participation at 6 months after the baseline outpatient visit The intervention is an alert to the provider to discuss lung cancer screening CT eligibility, for patients considered at high... Read More
Gender:
ALL
Ages:
Between 50 years and 77 years
Trial Updated:
06/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Lung Cancer, Health Screening, Early Cancer Detection, Deep Learning
Register for Updates
Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)
NCT04367311
Recruiting
The vast majority of patients with stage I (tumors ≥ 4cm), IIA, IIB (and select stage III) NSCLC are managed with upfront surgery, followed by adjuvant chemotherapy. However, relapse rates remain high and are primarily due to distant, metastatic disease. Previous meta-analysis evaluating the use of neo-adjuvant chemotherapy and adjuvant chemotherapy demonstrate a similar impact on improved disease free survival (DFS) and overall survival (OS). The role of checkpoint inhibitors has been proven to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: Banner MD Anderson Cancer Center, Gilbert, Arizona +9 locations
Conditions: Lung Cancer, NSCLC
Register for Updates
Integrated Cancer Repository for Cancer Research
NCT02012699
Recruiting
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
06/04/2025
Locations: Advent Health, Greenwood Village, Colorado +46 locations
Conditions: Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control, Gastrointestinal Stromal Tumors, Central Nervous System Tumor, Central Nervous System Cancer
Register for Updates
Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES
NCT05968898
Recruiting
This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.
Gender:
ALL
Ages:
Between 35 years and 89 years
Trial Updated:
06/04/2025
Locations: Penn Medicine University City, Philadelphia, Pennsylvania +2 locations
Conditions: Lung Cancer, Pulmonary Nodule, Solitary
Register for Updates
Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer Center
NCT06420206
Recruiting
To improve quality of life for participants with advanced cancer, support their families, and lower overall cost of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer, Gastrointestinal Cancer
Register for Updates
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: City of Hope, Duarte, California +9 locations
Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Register for Updates
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT04038619
Recruiting
This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effectively reduce the incidence of immune checkpoint inhibitor-induced diarrhea/colitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colitis, Diarrhea, Malignant Genitourinary System Neoplasm, Melanoma, Lung Cancer, Ovarian Cancer, Uterine Cancer, Breast Cancer, Cervical Cancer
Register for Updates
Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer
NCT07008664
Recruiting
The purpose of this research study is to test a new process for diagnosing lung cancer by examining changes to your DNA that can be detected from a blood test. The information we learn by doing this study could potentially help people in the future. Participants in this study will have blood samples collected, have their medical records reviewed by study personnel and fill out questionnaires at different time points during the study. Blood sample collection will occur during normal routine clin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: University of Maryland Baltimore Washington Medical Center, Glen Burnie, Maryland
Conditions: Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers
Register for Updates